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Abstract 
 
Colorectal cancer (CRC) develops in a step-wise fashion from a normal epithelium, through dysplastic 
adenomas into invasive carcinoma.  In addition to familial adenomatous polyposis and Lynch 
syndrome, approximately 10-35% of CRCs are familial in nature.  CRC screening and surveillance 
programs are based on an understanding of polyp natural history and rely on the ability to 
endoscopically remove pre-malignant lesions before they are capable of developing invasion.  There 
are however significant differences in these guidelines between the United Kingdom (UK) and the 
United States of America, in relation to the weight attributed to a family history of polyps.  Here we 
show using publicly available national datasets that these guideline differences unexpectedly 
generate inadequate screening recommendations for second-degree relatives of patients with CRC 
in the UK.  We validate our simple mathematical modelling of the clinical problem on a regional 
dataset as well as previously published study data to demonstrate correct interpretation.  We 
further discuss the implications of a family history of adenomas in the contemporary climate of the 
Bowel Cancer Screening Program and suggest a re-evaluation of the UK guidelines in light of this 
developing issue. 
 
What does this paper add? 
This paper, using simplistic mathematical modelling, describes a clinical problem driven through 
national differences in endoscopy guidelines that results in inappropriate screening of kindred of 
those with CRC.  The consequences of these differences are a number of preventable cancers 
occurring every year in the UK.  
 
  
The lifetime risk for colorectal cancer (CRC) is more than trebled for first-degree relatives (FDRs) of 
patients with CRC [1].  Although there are well-defined syndromes for some forms of familial CRC 
such as familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer 
(HNPCC), there exist many molecularly undefined, although still familial, alternative forms of CRC 
that are reported to account for between 10-35% of CRC cases [2, 3].  There are now population-
wide clinical guidelines that not only can estimate an individual’s risk for developing CRC but also 
guide screening and surveillance decisions.  Patients found to have an increased risk for CRC, in 
relation to family history, are generally offered further investigations, the gold-standard being 
colonoscopy.  The advantages of colonoscopy over alternative radiological investigations such as CT 
colonography are its combined diagnostic and therapeutic benefits.  Although improvements in 
molecular stratification have identified many more numerous subtypes of CRC than previously 
thought with different driver mutations or gene expression profiles, it remains generally accepted 
that the majority of CRCs still develop in the classical Vogelstein manner. Typically, this is described 
as a sequential acquisition of oncogenic events and loss of tumour suppressor activity, 
phenotypically characterised by the development of dysplastic adenomas and then invasive 
carcinoma from normal epithelium [4].  Thus, the oncological benefit in the endoscopic removal of 
pre-malignant adenomas is clear and well described, in that it prevents the development of invasive 
carcinoma which would otherwise require the patient to undergo surgical colectomy with possible 
adjuvant therapy. 
In the UK and the USA clinical guidelines linking endoscopic screening to family history differ in 
relation to the risk attributable to a family history of colorectal adenomas [5, 6].  In the UK, a family 
history of adenomas does not form part of the guidelines; whereas in the USA adenomas are 
identified as an independent risk factor requiring surveillance in relatives.  Whilst there are health 
economic issues to take into account relative to the benefit of including a family history of adenoma 
in screening guidelines, these differences generate some hidden potential clinical decision making 
pitfalls for individual patients.  We have previously shown, in a district general hospital setting, that 
patients undergoing polypectomy, who have a family history of CRC, although diminishing their own 
chances of developing CRC, paradoxically change the subsequent guidance recommendations for 
their off-spring [7].  The unintended effect of this altered risk calculation for the second-degree 
relatives (SDR) is that these patients would no longer be offered surveillance under current 
guidelines despite their own individual risk not having changed (Figure 1).  Here, we validate these 
local results, using publicly available data sets, at a population level using conservative estimates of 
burden. 
There are on average 41581 cases of CRC per annum in the UK of which 4158 will be familial, 
assuming only 10% of cases are familial in origin [8].  The lifetime risk of developing cancer in an 
individual who is a FDR of a patient with CRC is approximately 9% [9].  The Office for National 
Statistics states that on average there are 1.7 (2) children per family [10].  If each familial case 
therefore had two children and all these FDRs were identified as being at risk and offered 
colonoscopy then 748 (2*(4158*0.09)) potential cancers could be prevented by prophylactic 
polypectomy.  The FDRs inherited risk for CRC however remains unchanged although they would not 
have developed CRC.  Next, if all these FDRs subsequently have a further 2 children each (1497) then 
these SDRs’ management will be different according to whether they live in the UK or the USA.  In 
the UK, their parental adenomas will be not be classified by current guidelines as a risk factor and 
the SDR will not be offered surveillance.  In the USA however they would be offered surveillance 
based on the family history of adenomas alone.  Thus, theoretically in the UK, 135 patients per 
annum of these second-degree relatives (1497*0.09) could go on to develop familial inherited CRC 
through inadequate surveillance despite having a bona fide family history. 
In order to validate this highly simplistic and conservative national population model we applied the 
same approach to the region we had previously carried out our pilot study in: Cheltenham and 
Gloucester NHS Trust (C&G).  C&G serves a population of 612,000 equating to roughly 0.9% of the 
UK population.  C&G sees approximately 375 cases of CRC per annum.  Again, assuming 10% of these 
will be familial (38) then this will lead to 76 ‘at-risk’ FDRs.  If these patients all undergo surveillance 
endoscopy then this should lead to 6.84 (7) cases of prevented cancers per annum.  In our previously 
published work we identified 14 such cases over an 18 month period (i.e. 9 per annum); a not dis-
similar number to that which our model predicts. 
These relatively simplistic calculations validate our approach, showing it can calculate the rough 
numbers of patients at-risk of developing CRC through inadequate surveillance in the UK following 
current guidelines.  The calculated annual burden in the UK of this clinical problem is low - 135 per 
annum or 0.3% of total CRC numbers; although these are entirely avoidable deaths.  Given the small 
size of the problem however any form of prospective study to identify statistically different numbers 
of CRCs prevented as a result of a change to the current screening guidelines are unfeasible both in 
time and scale. 
From a health economic perspective, the NHS tariff for an adult diagnostic colonoscopy is £446 and 
for an uncomplicated colectomy around £5700.  From our calculations, the additional financial 
burden of endoscopy would be £668K (1497*446) whereas the cost without screening, assuming 
135 patients would subsequently develop cancer, of the surgery alone (excluding 
radiological/endoscopic diagnosis +/- chemotherapy) equates to near £770K.  Further, given the 
relatively small numbers of additional patients requiring colonoscopy per hospital we believe that 
this would have a negligible effect on already stretched endoscopy departments. 
Our estimation of the size of the clinical problem uses a conservative value of familial CRC incidence 
(10%).  If the same calculations are performed using the higher end quoted incidence (35%) then the 
number of avoidable CRC cases per annum reaches 472, with an associated endoscopy cost of 
~£2.4M with screening compared to the surgical cost per se of ~£2.7M without screening.  These 
calculations confirm that even without an exact knowledge of the incidence of familial CRC, taking 
both higher and lower published estimates, screening these at-risk patients makes clinical and 
economical sense. 
Our description of the current clinical problem of missed-kindred screening, will inevitably get worse 
somewhat with time, partly as a result of the bowel cancer screening program.  As the current 
program embeds and increasing numbers of cancers are ‘prevented’ by polypectomy with 
subsequent surveillance, those with non-classical (i.e. non-HNPCC/FAP) familial pre-disposition to 
cancer will no longer develop cancer, rather polyps alone.  However, their genetic/epigenetic CRC 
predisposition will still be transferred to a proportion of their children.  If the current guidelines are 
not changed we will see increasing numbers of these ‘at-risk’ FDRs also not being offered 
surveillance and many will inevitably develop CRC in a manner analogous to the current smaller scale 
SDR problem we describe earlier. 
We believe that we have demonstrated a hitherto under-appreciation of a small but entirely 
preventable clinical problem that has arisen fundamentally as a result of family history screening 
guidelines in the UK.  Perhaps, the bigger question to discuss as a community is whether a family 
history of polyps per se should be recognised, as per the US guidelines, as an independent risk factor 
for CRC.  There are a large number of studies in the literature demonstrating the additional risk 
posed by a family history of colorectal polyps.  A meta-analysis published in 2001 based on 9 
independent studies showed that the presence of an adenoma in a FDR generates an estimated 
relative risk (RR) of 1.99 (95% CI=1.55-2.55) for the individual [11].  Further, the authors also 
identified an association between age at when the adenoma was diagnosed and the RR; with an 
even higher RR in a FDR whose relative was diagnosed with adenomas at a young age (≤60y).  A 
more recent large-scale retrospective case-control study from the USA looked at the risk of 
adenomas and CRC in FDRs, as well as SDRs and third-degree relatives (TDR) of patients with an 
adenoma or advanced adenoma [12].  This study convincingly demonstrates that FDRs, SDRs and 
TDRs of those with either adenomas or advanced adenomas have a higher risk of developing either 
CRC or adenomas.  These recent data are in support of several other older studies showing similar 
findings [13-16]. 
The implications of these studies are that FDRs of those with adenomas should be offered 
endoscopic screening.  This has significant clinical, economic and logistical implications.  The 
morbidity of colonoscopy whilst small is not insignificant: intestinal perforation (1:1,000), bleeding 
(1:200) as well as bowel preparation related renal complications [17].  Indeed, these are certainly 
underestimates as this population group will more likely than chance require polypectomy due to 
their enhanced risk.  Further, a proportion of these patients will inevitably require elective operative 
intervention for CRC or non-endoscopically resectable polyps with all the associated risks of 
complications and death (2-4%).  Whilst the enhanced screening protocol proposed could decrease 
the number of patients presenting with more advanced CRC whether this would diminish overall 
mortality rather than disease-specific mortality is moot, topical and relevant [18]. 
The increased economic burden of colonoscopic screening in FDRs of those with adenomas would be 
huge given the prevalence of adenomas in the average risk patient equates to ~30% [19].  In addition 
to cost, the logistics of organising this in an IT-fragmented NHS will inevitably lead to missed cases or 
inappropriate intervention.  It follows that there will be a reliance on the patient having an in-depth 
knowledge of their relatives’ colonoscopy findings and histology in order, for example, to distinguish 
hyperplastic from dysplastic polyps.  There is good evidence that both patients and relatives have 
poor recall of these important data which will further complicate the process [20, 21].  Finally, there 
would be the issue of when to start screening in FDRs of those with adenomas.  Recent scientific 
advances propose that not all polyps are alike, for example sessile serrated polyps are generally 
over-represented by BRAF mutations.  The variable molecular landscape of these early lesions 
translates into different biological behaviour so in the future in addition to molecular stratification of 
CRCs there will be a need for a similar understanding of adenomas to guide both the patient’s 
surveillance and the timing of the FDRs initial colonoscopy.  Although clearly challenging, we feel 
these concepts need open discussion, to at least help inform consultations with individual patients.  
At the very minimum we feel that the presence of a family history of polyps should prompt inquiry 
into a history of CRC in the preceding generation and that these patients should be offered 
endoscopic screening on a case-by-case basis. 
  
Figure 1. Schematic representing the concept of inadequate screening in second-degree relatives 
of patients with colorectal cancer 
 
Index patient (A) is diagnosed with familial colorectal cancer, as such the FDRs undergo colonoscopic 
screening.  Case (B) inherits the parental predisposition to CRC but as a result of the colonoscopy has 
polyps removed.  SDR (C) of the index case (A) also inherits the cancer predisposition from parent (B) 
but because parent (B) only progressed so far as to developing polyps is not offered screening and as 
such goes onto develop CRC. 
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